Regulatory compliance – Page 36

Record retention failures during compliance audit – inspection evidence requirements

Addressing Record Retention Failures During Compliance Audits: A Practical Playbook In the pharmaceutical industry, record retention is paramount to ensuring compliance with regulatory requirements. Failures in this area can lead…

Inadequate worst-case selection during change control – regulatory deficiency risk

Addressing Inadequate Worst-Case Selection in Change Control Processes In the complex world of pharmaceutical manufacturing, one critical aspect that can lead to regulatory deficiencies is the inadequate selection of worst-case…

Record retention failures during validation lifecycle – inspection evidence requirements

Addressing Record Retention Failures During the Validation Lifecycle: An Inspection-Ready Playbook Record retention is a critical component of the validation lifecycle in pharmaceutical manufacturing. Failure to properly retain records can…

Inadequate worst-case selection during lifecycle management – risk-based validation alignment

Effective Strategies for Addressing Inadequate Worst-Case Selection in Lifecycle Management In pharmaceutical manufacturing, the importance of thorough validation during lifecycle management cannot be overstated. Inadequate worst-case selection can lead to…

ERES controls not implemented during system upgrade – preventing repeat Part 11 findings

Addressing ERES Control Failures During System Upgrades to Prevent Part 11 Noncompliance In an environment where regulatory compliance is paramount, the implementation of ERES controls plays a critical role, especially…

CSV compliance weak during change control – CAPA and revalidation strategy

Addressing Weaknesses in CSV Compliance During Change Control: A Practical Playbook Change control is an essential process in pharmaceutical manufacturing that ensures all modifications are documented, evaluated, and implemented without…

ERES controls not implemented during inspection walkthrough – inspection evidence requirements

Addressing ERES Control Issues During Inspection Walkthroughs In the realm of pharmaceutical manufacturing and quality control, the implementation of Electronic Records and Electronic Signatures (ERES) controls is critical. This is…

Incomplete validation lifecycle during site expansion – regulatory deficiency risk

Managing the Risks of Incomplete Validation Lifecycles During Pharmaceutical Site Expansion The pharmaceutical industry is under constant pressure to expand operations, which often leads to the complexities associated with incomplete…

Hybrid paper-electronic workflows uncontrolled during inspection walkthrough – preventing repeat Part 11 findings

Managing Hybrid Paper-Electronic Workflow Risks During Inspections The increasing reliance on hybrid paper-electronic workflows in pharmaceutical manufacturing can lead to control issues, particularly during regulatory inspections. This article presents a…

Validation gaps identified during lifecycle management – preventing repeat validation findings

Addressing Validation Fails Throughout the Lifecycle Management Process Validation gaps can pose significant challenges in pharmaceutical manufacturing and quality assurance, particularly during lifecycle management. Professionals in production, QC, QA, engineering,…

System access controls weak during system upgrade – risk-based ERES remediation

Addressing Weak System Access Controls During the System Upgrade: A Comprehensive Playbook In today’s pharmaceutical landscape, ensuring robust system access controls is paramount, especially during system upgrades. Weaknesses in these…

Management review ineffective during inspection readiness – QMS maturity gap analysis

“`html Addressing Ineffective Management Reviews During Inspection Readiness: A QMS Playbook In the dynamic environment of pharmaceutical manufacturing, it is critical that management reviews are both effective and efficient, particularly…